These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 7740450)

  • 1. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
    Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
    Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
    Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low molecular weight heparin on coagulation parameters and bleeding time in healthy volunteers.
    Warning A; Nies D; Wolf H; Welzel D
    Arzneimittelforschung; 1987 Jul; 37(7):847-9. PubMed ID: 2823841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
    Nimmerfall K; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Naumnik B; Pawlak K; Myśliwiec M
    Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
    Nilsen DW; Gøransson L; Larsen AI; Hetland O; Kierulf P
    Thromb Haemost; 1997 Jan; 77(1):57-61. PubMed ID: 9031450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.